David Butler, Ph.D., is the Chief Technology Officer at Hongene Biotech Corporation, a fully integrated CMO & CDMO that is focused on supplying raw materials and drugs to manufacturers and sponsor companies in the RNA therapeutics space, the scope of which includes mRNA, vaccines, oligonucleotides, gene editing, and gene therapy. Prior to Hongene, he led organizations driving platform discovery and development of oligonucleotide therapeutics as VP and Head of Medicinal Chemistry at Wave Life Sciences, VP and Head of Therapeutics Development at Alltrna, and VP and Head of Chemistry at Korro Bio. He also spent time as a Principal Scientist at Alnylam Pharmaceuticals developing early LNP technologies for siRNA delivery that were the progenitors of those used for mRNA related products today. He is passionate about team building, working with individuals and companies to help them succeed, and leveraging novel technologies to advance medicines more efficiently and safely.